nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.04.2013 | Headache (I Garza, Section Editor)

Vertigo as a Migraine Phenomenon

verfasst von: Neil Cherian

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a complex disorder with many different manifestations. There has been an increasing interest in the association of migraine and vertigo. Many different terms have been developed to describe this concept, the more popular being vestibular migraine, migrainous vertigo, and migraine-associated vertigo. The most commonly cited diagnostic criteria are that of Neuhauser though this has yet to be included in the International Classification of Headache Disorders (2^nd edition). At this time, there is a lack of consensus regarding migraine-related vertigo and its pathomechanism. Regardless, a few randomized controlled prospective studies have been performed to evaluate the efficacy of various medications. Topiramate has been shown to be effective for migraine-related vertigo. At this time there is no specific treatment for migraine-related dizziness outside of conventional migraine management. The genetics have yet to be fully realized though an autosomal dominant familial migraine vertigo disorder has been identified.

Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalagia. 2004;24 Suppl 1:1–160.

Bisdorff A, Von Brevern M, Lempert T, et al. Classification of vestibular symptoms: towards an international classification of vestibular disorders. J Vestib Res. 2009;19:1–13.PubMed

Lempert T, Neuhauser H. Epidemiology of vertigo, migraine, and vestibular migraine. J Neurol. 2009;256:333–8.PubMedCrossRef

Hsu LC, Wang SJ, Fuh JL. Prevalence and impact of migrainous vertigo in mid-life women. a community-based study. Cephalalgia. 2011;31:77–83.PubMedCrossRef

Dix MR, Hallpike CS. Pathology, symptoms, and diagnosis of certain disorders of the vestibular system. Proc R Soc Med. 1952;45:341–54.PubMed

American Academy of Otolaryngology-Head and Neck Foundation, Inc. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. Otolaryngol Head Neck Surg. 1995;113:181–5.CrossRef

•• Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T. The interrelations of migraine, vertigo, and migrainous vertigo. Neurology. 2001;56:436–41. This paper is of historical significance as it was an early paper discussing the overlap of migraine and vertigo and it also provided an approach to its classification.PubMedCrossRef

Strupp M, Versino M, Brandt T. Vestibular migraine. Handb Clin Neurol. 2010;97:755–71.PubMedCrossRef

• Eggers SD, Staab JP, Neff BA, et al. Investigation of the coherence of definite and probable vestibular migraine as distinct clinical entities. Otol Neurotol. 2011;32:1144–51. This is a recent article that discusses migraine and vertigo and identifies some of the pitfalls in the diagnosis of vestibular migraine. The results of the retrospective review do not allow for a meaningful separation between “definite” and “probable” vestibular migraine.PubMedCrossRef

10.

Ferber-Viart C, Dubreuil C, Duclaux R. Vestibular evoked myogenic potentials in humans. A review. Acta Otolaryngol. 1999;119:6–15.PubMedCrossRef

11.

Hong SM, Kim SK, Park CH, et al. Vestibular-evoked myogenic potentials in migrainous vertigo. Otolaryngol Head Neck Surg. 2011;144:284–7.PubMedCrossRef

12.

Szirmai A. Vestibular disorders in patients with migraine. Eur Arch Otorhinolaryngol. 1997;254:S55–7.PubMedCrossRef

13.

Bahmad Jr F, DePalma SR, Merchant SN, et al. Locus for familial migrainous vertigo disease maps to chromosome 5q35. Ann Oto Rhino Laryngol. 2009;118:670–6.

14.

Oh AK, Lee H, Jen JC, et al. Familial benign recurrent vertigo. Am J Med Genet. 2001;15:287–91.CrossRef

15.

Gode S, Celebisoy N, Kirazli T, Akyuz A, Bilgen C, Karapolat H, et al. Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache. 2010;50(1):77–84.

16.

Neuhauser H, Radtke A, von Brevern M, et al. Zolmitriptan for treatment of migrainous vertigo. A pilot randomized placebo-controlled trial. Neurology. 2003;60:882–3.PubMedCrossRef

17.

Gottshall KR, Moore RJ, Hoffer ME. Vestibular rehabilitation for migraine-associated dizziness. Int Tinnitus J. 2005;11:81–4.PubMed

18.

Whitney SL, Wrisley DM, Brown KE, et al. Physical therapy for migraine-related vestibulopathy and vestibular dysfunction with history of migraine. Laryngoscope. 2000;110:1528–34.PubMedCrossRef

19.

Young WB, Peres MF, Rozen TD. Modular theory of migraine. Cephalalgia. 2001;21:842–9.PubMedCrossRef

20.

Tepper SJ, Tepper DE. Breaking the cycle of medication overuse headache. Cleve Clin J Med. 2010;77:236–42.PubMedCrossRef

21.

Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway; perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8:89–99.PubMedCrossRef

22.

Murdin L, Davies RA, Bronstein AM. Vertigo as a migraine trigger. Neurology. 2009;25:638–42.CrossRef

23.

de Jong PT, de Jong JM, Cohen B, Jongkees LB. Ataxia and nystagmus induced by injection of local anesthetics in the Neck. Ann Neurol. 1977;1:240–6.PubMedCrossRef

24.

Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes—prolonged effects from a single injection. Pain. 2006;122:126–9.PubMedCrossRef

25.

Crevits L, Bosman T. Migraine-related vertigo towards a distinctive entity. Clin Neurol Neurosurg. 2005;107:82–7.PubMedCrossRef

26.

Baron EP, Cherian N, Tepper SJ. Role of greater occipital nerve blocks and trigger point injections for patients with dizziness and headache. Neurologist. 2011;17:312–7.PubMedCrossRef

27.

Volcy M, Sheftell FD, Tepper SJ, et al. Tinnitus in migraine: an allodynic symptom secondary to abnormal cortical functioning? Headache. 2005;45:1083–7.PubMedCrossRef

28.

Precht W, Shimazu H, Markham CH. A mechanism of central compensation of vestibular function following hemilabyrinthectomy. J Neurophysiol. 1966;29:996–1010.PubMed

29.

Rudge R, Chambers BR. Physiological basis for enduring vestibular symptoms. J Neurol Neurosurg Psychiatry. 1982;45:126–30.PubMedCrossRef

30.

Viirre ES, Baloh RW. Migraine as a cause of sudden hearing loss. Headache. 1996;36:24–8.PubMedCrossRef

31.

Lee H, Lopez I, Ishiyama A, et al. Can migraine damage the inner ear? Arch Neurol. 2000;57:1631–4.PubMedCrossRef

32.

Stach B. Speech audiometry and other behavioral measures. In: Stach B, editor. Clinical audiology. An introduction. San Diego: Singular Publishing; 1998. p. 241–3.

33.

Cherian N. Improvement in hearing following occipital nerve injection. Association for Research in Otolaryngology. Poster presentation. Winter, 2008.

34.

Kavcic V, Vaughn W, Duffy CJ. Distinct visual motion processing impairments in aging and Alzheimer’s disease. Vision Res. 2011;51:386–95.PubMedCrossRef

35.

Wray SH, Mijovic-Prelec D, Kosslyn SM. Visual processing in migraineurs. Brain. 1995;118:25–35.PubMedCrossRef

36.

Cherian N, Kriegler J. Systems engineering approach to migraine and dizziness. American Headache Society meeting. Poster presentation. June, 2007.

Titel: Vertigo as a Migraine Phenomenon
verfasst von: Neil Cherian
Publikationsdatum: 01.04.2013
Verlag: Current Science Inc.
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 4/2013
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-013-0343-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Agrypnia Excitata

Nontraumatic Subarachnoid Hemorrhage of the Convexity

Daytime Sleepiness and Myotonic Dystrophy

Chronopharmacology of Anti-Convulsive Therapy

Phenotypic Spectrum of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)